AlloHeme test accurately predicts relapse post-allo-HSCT in AML and MDS, with a median lead time of 36 days. The ACROBAT study involved 287 patients, showing significant predictive value of increased ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results